- Home
- SPCE vs SKYE Comparison
SPCE vs SKYE Comparison
Compare SPCE & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPCE
- SKYE
- Stock Information
- Founded
- SPCE 2017
- SKYE 2012
- Country
- SPCE United States
- SKYE United States
- Employees
- SPCE N/A
- SKYE N/A
- Industry
- SPCE Transportation Services
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- SPCE Consumer Discretionary
- SKYE Health Care
- Exchange
- SPCE Nasdaq
- SKYE Nasdaq
- Market Cap
- SPCE 226.9M
- SKYE 121.8M
- IPO Year
- SPCE N/A
- SKYE N/A
- Fundamental
- Price
- SPCE $3.92
- SKYE $1.54
- Analyst Decision
- SPCE Hold
- SKYE Strong Buy
- Analyst Count
- SPCE 5
- SKYE 5
- Target Price
- SPCE $10.60
- SKYE $14.75
- AVG Volume (30 Days)
- SPCE 5.5M
- SKYE 1.9M
- Earning Date
- SPCE 11-13-2025
- SKYE 11-12-2025
- Dividend Yield
- SPCE N/A
- SKYE N/A
- EPS Growth
- SPCE N/A
- SKYE N/A
- EPS
- SPCE N/A
- SKYE N/A
- Revenue
- SPCE $1,698,000.00
- SKYE N/A
- Revenue This Year
- SPCE N/A
- SKYE N/A
- Revenue Next Year
- SPCE $2,908.26
- SKYE N/A
- P/E Ratio
- SPCE N/A
- SKYE N/A
- Revenue Growth
- SPCE N/A
- SKYE N/A
- 52 Week Low
- SPCE $2.18
- SKYE $1.14
- 52 Week High
- SPCE $8.19
- SKYE $5.96
- Technical
- Relative Strength Index (RSI)
- SPCE 49.20
- SKYE 33.15
- Support Level
- SPCE $3.54
- SKYE $1.31
- Resistance Level
- SPCE $4.17
- SKYE $1.66
- Average True Range (ATR)
- SPCE 0.36
- SKYE 0.10
- MACD
- SPCE -0.05
- SKYE 0.06
- Stochastic Oscillator
- SPCE 22.49
- SKYE 51.28
About SPCE Virgin Galactic Holdings Inc.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.